Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways
10.1038/nm1008
Crossref journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
Bibliography

Björkbacka, H., Kunjathoor, V. V., Moore, K. J., Koehn, S., Ordija, C. M., Lee, M. A., Means, T., Halmen, K., Luster, A. D., Golenbock, D. T., & Freeman, M. W. (2004). Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine, 10(4), 416–421.

Authors 11
  1. Harry Björkbacka (first)
  2. Vidya V Kunjathoor (additional)
  3. Kathryn J Moore (additional)
  4. Stephanie Koehn (additional)
  5. Christine M Ordija (additional)
  6. Melinda A Lee (additional)
  7. Terry Means (additional)
  8. Kristen Halmen (additional)
  9. Andrew D Luster (additional)
  10. Douglas T Golenbock (additional)
  11. Mason W Freeman (additional)
References 33 Referenced 510
  1. Lusis, A.J. Atherosclerosis. Nature 407, 233–241 (2000). (10.1038/35025203) / Nature by AJ Lusis (2000)
  2. Ismail, A., Khosravi, H. & Olson, H. The role of infection in atherosclerosis and coronary artery disease: a new therapeutic target. Heart Dis. 1, 233–240 (1999). / Heart Dis. by A Ismail (1999)
  3. Epstein, S.E. et al. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler. Thromb. Vasc. Biol. 20, 1417–1420 (2000). (10.1161/01.ATV.20.6.1417) / Arterioscler. Thromb. Vasc. Biol. by SE Epstein (2000)
  4. Frishman, W.H. & Ismail, A.A. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol. Rev. 10, 199–210 (2002). (10.1097/00045415-200207000-00004) / Cardiol. Rev. by WH Frishman (2002)
  5. Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999). (10.1056/NEJM199901143400207) / N. Engl. J. Med. by R Ross (1999)
  6. Binder, C.J. et al. Innate and acquired immunity in atherogenesis. Nat. Med. 8, 1218–26 (2002). (10.1038/nm1102-1218) / Nat. Med. by CJ Binder (2002)
  7. Chow, J.C., Young, D.W., Golenbock, D.T., Christ, W.J. & Gusovsky, F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274, 10689–10692 (1999). (10.1074/jbc.274.16.10689) / J. Biol. Chem. by JC Chow (1999)
  8. Xu, X.H. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104, 3103–3108 (2001). (10.1161/hc5001.100631) / Circulation by XH Xu (2001)
  9. Vink, A. et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106, 1985–1990 (2002). (10.1161/01.CIR.0000032146.75113.EE) / Circulation by A Vink (2002)
  10. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185–192 (2002). (10.1056/NEJMoa012673) / N. Engl. J. Med. by S Kiechl (2002)
  11. Edfeldt, K., Swedenborg, J., Hansson, G.K. & Yan, Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158–1161 (2002). (10.1161/circ.105.10.1158) / Circulation by K Edfeldt (2002)
  12. Wright, S.D. et al. Infectious agents are not necessary for murine atherogenesis. J. Exp. Med. 191, 1437–1442 (2000). (10.1084/jem.191.8.1437) / J. Exp. Med. by SD Wright (2000)
  13. Tanaka, E. et al. Disparity of MCP-1 mRNA and protein expressions between the carotid artery and the aorta in WHHL rabbits: one aspect involved in the regional difference in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 244–250 (2003). (10.1161/01.ATV.0000051876.26766.FD) / Arterioscler. Thromb. Vasc. Biol. by E Tanaka (2003)
  14. Mach, F. The role of chemokines in atherosclerosis. Curr. Atheroscler. Rep. 3, 243–251 (2001). (10.1007/s11883-001-0067-y) / Curr. Atheroscler. Rep. by F Mach (2001)
  15. Burke-Gaffney, A., Brooks, A.V. & Bogle, R.G. Regulation of chemokine expression in atherosclerosis. Vascul. Pharmacol. 38, 283–292 (2002). (10.1016/S1537-1891(02)00253-7) / Vascul. Pharmacol. by A Burke-Gaffney (2002)
  16. Gosling, J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773–778 (1999). (10.1172/JCI5624) / J. Clin. Invest. by J Gosling (1999)
  17. Boring, L., Gosling, J., Cleary, M. & Charo, I.F. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894–897 (1998). (10.1038/29788) / Nature by L Boring (1998)
  18. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143–150 (1998). (10.1016/S1074-7613(00)80596-8) / Immunity by O Adachi (1998)
  19. Kirii, H. et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656–660 (2003). (10.1161/01.ATV.0000064374.15232.C3) / Arterioscler. Thromb. Vasc. Biol. by H Kirii (2003)
  20. Elhage, R. et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234–240 (2003). (10.1016/S0008-6363(03)00343-2) / Cardiovasc. Res. by R Elhage (2003)
  21. Bulut, Y. et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J. Immunol. 168, 1435–1440 (2002). (10.4049/jimmunol.168.3.1435) / J. Immunol. by Y Bulut (2002)
  22. Walton, K.A. et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 278, 29661–29666 (2003). (10.1074/jbc.M300738200) / J. Biol. Chem. by KA Walton (2003)
  23. Raschi, E. et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101, 3495–3500 (2003). (10.1182/blood-2002-08-2349) / Blood by E Raschi (2003)
  24. Kanters, E. et al. Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 112, 1176–1185 (2003). (10.1172/JCI200318580) / J. Clin. Invest. by E Kanters (2003)
  25. Pahl, H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853–6866 (1999). (10.1038/sj.onc.1203239) / Oncogene by HL Pahl (1999)
  26. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R. & Willoughby, D.A. Possible new role for NF-κB in the resolution of inflammation. Nat. Med. 7, 1291–1297 (2001). (10.1038/nm1201-1291) / Nat. Med. by T Lawrence (2001)
  27. Moore, K.J. et al. Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J. Immunol. 165, 4272–4280 (2000). (10.4049/jimmunol.165.8.4272) / J. Immunol. by KJ Moore (2000)
  28. Kunjathoor, V.V., Wilson, D.L. & LeBoeuf, R.C. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest. 97, 1767–1773 (1996). (10.1172/JCI118604) / J. Clin. Invest. by VV Kunjathoor (1996)
  29. Kunjathoor, V.V., Chiu, D.S., O'Brien, K.D. & LeBoeuf, R.C. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 462–468 (2002). (10.1161/hq0302.105378) / Arterioscler. Thromb. Vasc. Biol. by VV Kunjathoor (2002)
  30. Tangirala, R.K., Rubin, E.M. & Palinski, W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320–2328 (1995). (10.1016/S0022-2275(20)39713-3) / J. Lipid Res. by RK Tangirala (1995)
  31. Saal, L.H. et al. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol. 3, SOFTWARE0003 (2002).
  32. Moore, K.J., Naito, T., Martin, C. & Kelley, V.R. Enhanced response of macrophages to CSF-1 in autoimmune mice: a gene transfer strategy. J. Immunol. 157, 433–440 (1996). (10.4049/jimmunol.157.1.433) / J. Immunol. by KJ Moore (1996)
  33. Kunjathoor, V.V. et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277, 49982–49988 (2002). (10.1074/jbc.M209649200) / J. Biol. Chem. by VV Kunjathoor (2002)
Dates
Type When
Created 21 years, 5 months ago (March 21, 2004, 1:58 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 7:38 p.m.)
Indexed 5 days, 10 hours ago (Aug. 29, 2025, 6:23 a.m.)
Issued 21 years, 5 months ago (March 14, 2004)
Published 21 years, 5 months ago (March 14, 2004)
Published Online 21 years, 5 months ago (March 14, 2004)
Published Print 21 years, 5 months ago (April 1, 2004)
Funders 0

None

@article{Bj_rkbacka_2004, title={Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways}, volume={10}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/nm1008}, DOI={10.1038/nm1008}, number={4}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={Björkbacka, Harry and Kunjathoor, Vidya V and Moore, Kathryn J and Koehn, Stephanie and Ordija, Christine M and Lee, Melinda A and Means, Terry and Halmen, Kristen and Luster, Andrew D and Golenbock, Douglas T and Freeman, Mason W}, year={2004}, month=mar, pages={416–421} }